Mizuho Maintains Outperform on Autolus Therapeutics, Lowers Price Target to $10
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Salim Syed maintains Autolus Therapeutics (NASDAQ:AUTL) with a Outperform and lowers the price target from $12 to $10.
Mizuho analyst Salim Syed maintains Autolus Therapeutics (NASDAQ:AUTL) with a Outperform and lowers the price target from $12 to $10.